We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Demonstrating Versatility of Single-Domain Antibodies in Antibody Therapeutics Development

Demonstrating Versatility of Single-Domain Antibodies in Antibody Therapeutics Development content piece image

The family of Camelidae possess a unique repertoire of fully functional antibodies, which are naturally devoid of light chains. Since the discovery of camelid heavy chain antibodies in the early 90’s, the use of their pared down version, known as single domain antibodies (sdAbs) or VHH ligands, has seen a tremendous uptake in various fields.

sdAbs harbor the full antigen-binding capacity of the original heavy chain antibody, but the small size (~12-15kD) enables them to reach epitopes normally unavailable for conventional IgGs. These ligands bind their targets with high affinity and selectivity. Due to their tunable specificity, high stability and efficient production in low eukaryotic species, this technology has been embraced by multiple disciplines of research and medicine.

The CaptureSelect™ camelid single domain antibody technology has been developed for the routine purification of a wide range of biologics, including therapeutic antibodies and antibody fragments. In addition to purification in drug development, sdAbs also have specific advantages useful for the development of analytical methods.

During this presentation we will outline the versatility of these ligands and show examples of how they can be used for purification, quantification and characterization of different antibody formats.

Attend this webinar to discover:

  • The versatility of single domain antibody technology in antibody drug development
  • The sdAbs which help increase efficiency of antibody purification
  • The development of analytical methods based on sdAb technology
Pim Hermans
Pim Hermans
Head of Ligand Discovery, Thermo Fisher Scientific